Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change

C Czech; H Förstl; F Hentschel; U Mönning; C Besthorn; C Geiger-Kabisch; H Sattel; C Masters; K Beyreuther

doi:10.1007/BF02191587

Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change

Eur Arch Psychiatry Clin Neurosci. 1994;243(5):291-2. doi: 10.1007/BF02191587.

Authors

C Czech¹, H Förstl, F Hentschel, U Mönning, C Besthorn, C Geiger-Kabisch, H Sattel, C Masters, K Beyreuther

Affiliation

¹ Center for Molecular Biology, Heidelberg, Germany.

PMID: 8172944
DOI: 10.1007/BF02191587

Abstract

The prevalence of the apolipoprotein E-4 allele (ApoE-4) was significantly higher in a referral population of 40 patients with clinically diagnosed Alzheimer's disease than in a sample of non-demented elderly controls (P < 0.01). The highest plasma cholesterol levels were found in demented patients homozygotic for Apo E-4, but no significant increases of glucose, triglycerides and thyroxine or of leuko-araiosis and brain infarcts were verified in this preliminary study.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Alleles
Alzheimer Disease / diagnosis
Alzheimer Disease / genetics*
Alzheimer Disease / pathology
Apolipoprotein E4
Apolipoproteins E / genetics*
Brain / pathology*
Cerebral Infarction / diagnosis
Cerebral Infarction / genetics
Cerebral Infarction / pathology
Cholesterol / blood*
Chromosomes, Human, Pair 19*
Female
Genetic Carrier Screening
Genotype
Humans
Male
Middle Aged
Risk Factors

Substances

Apolipoprotein E4
Apolipoproteins E
Cholesterol